Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA ...

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming ...

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...

Here are the top 5 biosimilar articles for the week of April 21, 2025. Number 5: Trastuzumab biosimilars saw significant ...

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply ...